Genetics and Genetic Biomarkers in Sporadic Colorectal Cancer

Gastroenterology

Volumn 149, Issue 5, 2015, Pages 1177-1190.e3

  Carethers, John M ^a   Jung, Barbara H ^b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Chromosomal Instability; CIMP; Genomic Instability; Microsatellite Instability

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; ACTIVIN RECEPTOR 2; APC PROTEIN; B RAF KINASE; BETA CATENIN; BONE MORPHOGENETIC PROTEIN 2; CD9 ANTIGEN; DNA POLYMERASE; K RAS PROTEIN; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN MSH3; PROTEIN MSH6; PROTEIN P53; SMAD4 PROTEIN; SMAD7 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKER; GENETIC MARKER;

ARTICLE; CHROMOSOMAL INSTABILITY; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; GENE MUTATION; GENETIC ASSOCIATION; HETEROZYGOSITY LOSS; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MISMATCH REPAIR; PHENOTYPE; PRIORITY JOURNAL; COLORECTAL TUMOR; GENE EXPRESSION REGULATION; GENETIC MARKER; GENETIC PREDISPOSITION; GENETICS; GENOME-WIDE ASSOCIATION STUDY; MUTATION; PROCEDURES; PROGNOSIS;

COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOME-WIDE ASSOCIATION STUDY; HUMANS; MICRORNAS; MICROSATELLITE INSTABILITY; MUTATION; PROGNOSIS;

EID: 84943234285     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2015.06.047     Document Type: Article

References (148)

1. A.G. Zauber, S.J. Winawer, M.J. O'Brien, and et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths N Engl J Med 366 2012 687 696
2. R. Nishihara, S. Ogino, and A.T. Chan Colorectal-cancer incidence and mortality after screening N Engl J Med 369 2013 2355
3. A. Shaukat, S.J. Mongin, M.S. Geisser, and et al. Long-term mortality after screening for colorectal cancer N Engl J Med 369 2013 1106 1114
4. C.R. Boland, F.A. Sinicrope, D.E. Brenner, and et al. Colorectal cancer prevention and treatment Gastroenterology 118 Suppl 1 2000 S115 S128
5. B. Vogelstein, N. Papadopoulos, V.E. Velculescu, and et al. Cancer genome landscapes Science 339 2013 1546 1558
6. C. Tomasetti, L. Marchionni, M.A. Nowak, and et al. Only three driver gene mutations are required for the development of lung and colorectal cancers Proc Natl Acad Sci U S A 112 2015 118 123
7. Cancer Genome Atlas Network Comprehensive molecular characterization of human colon and rectal cancer Nature 487 2012 330 337
8. B. Zhang, J. Wang, X. Wang, et al. NCI CPTAC Proteogenomic characterization of human colon and rectal cancer Nature 513 2014 382 387
9. L.A. Garraway, and E.S. Lander Lessons from the cancer genome Cell 153 2013 17 37
10. E.R. Fearon Molecular genetics of colorectal cancer Annu Rev Pathol 6 2011 479 507
11. W.M. Grady, and J.M. Carethers Genomic and epigenetic instability in colorectal cancer pathogenesis Gastroenterology 135 2008 1079 1099
12. B. Jung, R.T. Doctolero, A. Tajima, and et al. Loss of activin receptor type 2 protein expression in microsatellite unstable colorectal cancers Gastroenterology 126 2004 654 659
13. B.H. Jung, S.E. Beck, J. Cabral, and et al. Activin type 2 receptor restoration in MSI-H colon cancer suppresses growth and enhances migration with activin Gastroenterology 132 2007 633 644
14. B.H. Jung, J. Gomez, E. Chau, and et al. Activin signaling in microsatellite stable (MSS) colon cancers is disrupted by a combination of genetic and epigenetic mechanisms PLoS One 4 2009 e8308
15. P. Broderick, L. Carvajal-Carmona, and et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk Nat Genet 39 2007 1315 1317
16. M.G. Dunlop, S.E. Dobbins, S.M. Farrington, and et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk Nat Genet 44 2012 770 776
17. R.S. Houlston, J. Cheadle, S.E. Dobbins, and et al. Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33 Nat Genet 42 2010 973 977
18. C.M. Hutter, M.L. Slattery, D.J. Duggan, and et al. Characterization of the association between 8q24 and colon cancer: gene-environment exploration and meta-analysis BMC Cancer 10 2010 670
19. E. Jaeger, E. Webb, K. Howarth, and et al. Common genetic variants at the CRAC1 (HMPS) locus on chromosome 15q13.3 influence colorectal cancer risk Nat Genet 40 2008 26 28
20. W.H. Jia, B. Zhang, K. Matsuo, and et al. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer Nat Genet 45 2013 191 196
21. J.D. Kocarnik, C.M. Hutter, M.L. Slattery, and et al. Characterization of 9p24 risk locus and colorectal adenoma and cancer: gene-environment interaction and meta-analysis Cancer Epidemiol Biomarkers Prev 19 2010 3131 3139
22. U. Peters, C.M. Hutter, L. Hsu, and et al. Meta-analysis of new genome-wide association studies of colorectal cancer risk Hum Genet 131 2012 217 234
23. U. Peters, S. Jiao, F.R. Schumacher, and et al. Identification of genetic susceptibility loci for colorectal tumors in a genome-wide meta-analysis Gastroenterology 144 2013 799 807
24. I. Tomlinson, E. Webb, L. Carvajal-Carmona, and et al. A genome-wide association scan of tag SNPs identifies a susceptibility variant for colorectal cancer at 8q24.21 Nat Genet 39 2007 984 988
25. I.P. Tomlinson, E. Webb, L. Carvajal-Carmona, and et al. A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3 Nat Genet 40 2008 623 630
26. B.W. Zanke, C.M. Greenwood, J. Rangrej, and et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24 Nat Genet 39 2007 989 994
27. E.D. Kantor, C.M. Hutter, J. Minnier, and et al. Gene-environment interaction involving recently identified colorectal cancer susceptibility loci Cancer Epidemiol Biomarkers Prev 23 2014 1824 1833
28. R.S. Houlston, E. Webb, P. Broderick, and et al. Meta-analysis of genome-wide association data identifies four new susceptibility loci for colorectal cancer Nat Genet 40 2008 1426 1435
29. A. Tenesa, S.M. Farrington, J.G. Prendergast, and et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21 Nat Genet 40 2008 631 637
30. A. Tenesa, and M.G. Dunlop New insights into the aetiology of colorectal cancer from genome-wide association studies Nat Rev Genet 10 2009 353 358
31. N. Whiffin, F.J. Hosking, S.M. Farrington, and et al. Identification of susceptibility loci for colorectal cancer in a genome-wide meta-analysis Hum Mol Genet 23 2014 4729 4737
32. B. Zhang, W.H. Jia, K. Matsuda, and et al. Large-scale genetic study in East Asians identifies six new loci associated with colorectal cancer risk Nat Genet 46 2014 533 542
33. S.L. Schmit, F.R. Schumacher, C.K. Edlund, and et al. A novel colorectal cancer risk locus at 4q32.2 identified from an international genome-wide association study Carcinogenesis 35 2014 2512 2519
34. H. Wang, T. Burnett, S. Kono, and et al. Trans-ethnic genome-wide association study of colorectal cancer identifies a new susceptibility locus in VTI1A Nat Commun 5 2014 4613
35. L.G. Carvajal-Carmona, J.B. Cazier, A.M. Jones, and et al. Fine-mapping of colorectal cancer susceptibility loci at 8q23.3, 16q22.1 and 19q13.11: refinement of association signals and use of in silico analysis to suggest functional variation and unexpected candidate target genes Hum Mol Genet 20 2011 2879 2888
36. J. Hutchison, Z. Cohen, B.C. Onyeagucha, and et al. How microRNAs influence both hereditary and inflammatory-mediated colon cancers Cancer Genet 206 2013 309 316
37. B.D. Adams, A.L. Kasinski, and F.J. Slack Aberrant regulation and function of microRNAs in cancer Curr Biol 24 2014 R762 R776
38. A.L. Kasinski, and F.J. Slack MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy Nat Rev Cancer 11 2011 849 864
39. N. Valeri, P. Gasparini, C. Braconi, and et al. MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2) Proc Natl Acad Sci U S A 107 2010 21098 21103
40. A.J. Schetter, S.Y. Leung, J.J. Sohn, and et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma JAMA 299 2008 425 436
41. F.E. Ahmed miRNA as markers for the diagnostic screening of colon cancer Expert Rev Anticancer Ther 14 2014 463 485
42. H. Okayama, A.J. Schetter, and C.C. Harris MicroRNAs and inflammation in the pathogenesis and progression of colon cancer Dig Dis 30 Suppl 2 2012 9 15
43. C. Palles, J.B. Cazier, K.M. Howarth, and et al. Germline mutations affecting the proofreading domains of POLE and POLD1 predispose to colorectal adenomas and carcinomas Nat Genet 45 2013 136 144
44. J.M. Carethers Unwinding the heterogeneous nature of hamartomatous polyposis syndromes JAMA 294 2005 2498 2500
45. Y. Samuels, Z. Wang, A. Bardelli, and et al. High frequency of mutations of the PIK3CA gene in human cancers Science 304 2004 554
46. A. Goel, C.N. Arnold, D. Niedzwiecki, and et al. Frequent inactivation of PTEN by promoter hypermethylation in microsatellite instability-high sporadic colorectal cancers Cancer Res 64 2004 3014 3021
47. B.H. Jung, S.E. Beck, and J.M. Carethers Bone morphogenetic protein (BMP) and activin signaling in colon cancer Curr Cancer Rep 4 2008 71 76
48. S.E. Beck, B.H. Jung, A. Fiorino, and et al. Bone morphogenetic protein signaling and growth suppression in colon cancer Am J Physiol Gastrointest Liver Physiol 291 2006 G135 G145
49. E.R. Fearon, and J.M. Carethers Molecular subtyping of colorectal cancer - time to explore both intertumoral and intratumoral heterogeneity to evaluate patient outcome Gastroenterology 148 2015 10 13
50. B. Deveraj, A. Lee, B.L. Cabrera, and et al. Relationship of EMAST and microsatellite instability among patients with rectal cancer J Gastrointest Surg 14 2010 1521 1528
51. M. Garcia, C. Choi, H.R. Kim, and et al. Association between recurrent metastasis from stage II and III primary colorectal tumors and moderate microsatellite instability Gastroenterology 143 2012 48 50
52. C.R. Boland, S.N. Thibodeau, S.R. Hamilton, and et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer Cancer Res 58 1998 5248 5257
53. C.R. Boland, and A. Goel Microsatellite instability in colorectal cancer Gastroenterology 138 2010 2073 2087
54. M.F. Kane, M. Loda, G.M. Gaida, and et al. Methylation of the hMLH1 promoter correlates with lack of expression of hMLH1 in sporadic colon tumors and mismatch repair-defective human tumor cell lines Cancer Res 57 1997 808 811
55. J.G. Herman, A. Umar, K. Polyak, and et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma Proc Natl Acad Sci U S A 95 1998 6870 6875
56. M.L. Veigl, L. Kasturi, J. Olechnowicz, and et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers Proc Natl Acad Sci U S A 95 1998 8698 8702
57. Y. Schwitalle, M. Kloor, S. Eiermann, and et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers Gastroenterology 134 2008 988 997
58. B. Leggett, and V. Whitehall Role of the serrated pathway in colorectal cancer pathogenesis Gastroenterology 138 2010 2088 2100
59. D.K. Chang, L. Ricciardiello, A. Goel, and et al. Steady-state regulation of the human DNA mismatch repair system J Biol Chem 275 2000 29178
60. S. Popat, R. Hubner, and R.S. Houlston Systematic review of microsatellite instability and colorectal cancer prognosis J Clin Oncol 23 2005 609 618
61. D.T. Le, J.N. Uram, H. Wang, and et al. PD-1 blockade in tumors with mismatch-repair deficiency N Engl J Med 372 2015 2509 2520
62. C.M. Ribic, D.J. Sargent, M.J. Moore, and et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer N Engl J Med 349 2003 247 257
63. J.M. Carethers, E.J. Smith, C.A. Behling, and et al. Use of 5-fluorouracil and survival in patients with microsatellite unstable colorectal cancer Gastroenterology 126 2004 394 401
64. A. Tajima, M.T. Hess, B.L. Cabrera, and et al. The mismatch repair complex hMutSα recognizes 5-fluoruracil-modified DNA: implications for chemosensitivity and resistance Gastroenterology 127 2004 1678 1684
65. W.-S. Jo, and J.M. Carethers Chemotherapeutic implications in microsatellite unstable colorectal cancer Cancer Biomarkers 2 2006 51 60
66. H. Chung, J. Chaudhry, C.G. Lopez, and et al. Cyclin E and histone H3 are regulated by 5-fluorouracil in a DNA mismatch repair-dependent manner Cancer Biol Ther 10 2010 1147 1156
67. A. Tajima, M. Iwaizumi, S. Tseng-Rogenski, and et al. Both hMutSα and hMutSβ complexes participate in 5-fluoruracil cytotoxicity PLoS One 6 2011 e28117
68. M. Iwaizumi, S. Tseng-Rogenski, and J.M. Carethers DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells Cancer Biol Ther 12 2011 756 764
69. E.M. Webber, J.S. Lin, and E.P. Whitlock Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction PLoS Curr 2 2010 2
70. G. Srivastava, L.A. Renfro, R.J. Behrens, and et al. Prospective multicenter study of the impact of oncotype DX colon cancer assay results on treatment recommendations in stage II colon cancer patients Oncologist 19 2014 492 497
71. + T cell infiltration in colon cancer PLoS One 9 2014 e100461
72. J.L. Tsao, Y. Yatabe, R. Salovaara, and et al. Genetic reconstruction of individual colorectal tumor histories Proc Natl Acad Sci U S A 97 2000 1236 1241
73. J.R. Jass Serrated route to colorectal cancer: back street or super highway? J Pathol 193 2001 283 285
74. J.M. Carethers One colon lumen but two organs Gastroenterology 141 2011 411 412
75. N.J. Llosa, M. Cruise, A. Tam, and et al. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints Cancer Discov 5 2015 43 51
76. J.M. Carethers Differentiating Lynch-like from Lynch syndrome Gastroenterology 146 2014 602 604
77. A.R. Mensenkamp, I.P. Vogelaar, W.A. van Zelst-Stams, and et al. Somatic mutations in MLH1 and MSH2 are a frequent cause of mismatch-repair deficiency in Lynch syndrome-like tumors Gastroenterology 146 2014 643 646.e8
78. S. Haraldsdottir, H. Hampel, J. Tomsic, and et al. Colon and endometrial cancers with mismatch repair deficiency can arise from somatic, rather than germline, mutations Gastroenterology 147 2014 1308 1316
79. M. Rodríguez-Soler, L. Pérez-Carbonell, C. Guarinos, and et al. Risk of cancer in cases of suspected lynch syndrome without germline mutation Gastroenterology 144 2013 926 932
80. S.Y. Kang, C.K. Park, D.K. Chang, and et al. Lynch-like syndrome: characterization and comparison with EPCAM deletion carriers Int J Cancer 136 2015 1568 1578
81. D.J. Weisenberger, K.D. Siegmund, M. Campan, and et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer Nat Genet 38 2006 787 793
82. T. Tahara, E. Yamamoto, P. Madireddi, and et al. Colorectal carcinomas with CpG island methylator phenotype 1 frequently contain mutations in chromatin regulators Gastroenterology 146 2014 530 538
83. K.E. Bachman, B.H. Park, I. Rhee, and et al. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene Cancer Cell 3 2003 89 95
84. R.A. Hinshelwood, J.R. Melki, L.I. Huschtscha, and et al. Aberrant de novo methylation of the p16INK4A CpG island is initiated post gene silencing in association with chromatin remodelling and mimics nucleosome positioning Hum Mol Genet 18 2009 3098 3109
85. D. Limsui, R.A. Vierkant, L.S. Tillmans, and et al. Cigarette smoking and colorectal cancer risk by molecularly defined subtypes J Natl Cancer Inst 102 2010 1012 1022
86. K. Ichimura Molecular pathogenesis of IDH mutations in gliomas Brain Tumor Pathol 29 2012 131 139
87. L. Barault, C. Charon-Barra, V. Jooste, and et al. Hypermethylator phenotype in sporadic colon cancer: study on a population-based series of 582 cases Cancer Res 68 2008 8541 8546
88. T. Hinoue, D.J. Weisenberger, C.P. Lange, and et al. Genome-scale analysis of aberrant DNA methylation in colorectal cancer Genome Res 22 2012 271 282
89. M. Bettington, N. Walker, C. Rosty, and et al. Critical appraisal of the diagnosis of the sessile serrated adenoma Am J Surg Pathol 38 2014 158 166
90. Y. Luo, C.J. Wong, A.M. Kaz, and et al. Differences in DNA methylation signatures reveal multiple pathways of progression from adenoma to colorectal cancer Gastroenterology 147 2014 418 429
91. R. Jover, T.P. Nguyen, L. Pérez-Carbonell, and et al. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer Gastroenterology 140 2011 1174 1181
92. B. Iacopetta, K. Kawakami, and T. Watanabe Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil-responsive subgroup? Int J Clin Oncol 13 2008 498 503
93. L. Shen, M. Toyota, Y. Kondo, and et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer Proc Natl Acad Sci U S A 104 2007 18654 18659
94. S. Shiovitz, M.M. Bertagnolli, L.A. Renfro, et al. Alliance for Clinical Trials in Oncology CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer Gastroenterology 147 2014 637 645
95. T.F. Imperiale, D.F. Ransohoff, S.H. Itzkowitz, and et al. Multitarget stool DNA testing for colorectal-cancer screening N Engl J Med 370 2014 1287 1297
96. E.R. Fearon, and B. Vogelstein A genetic model for colorectal tumorigenesis Cell 61 1990 759 767
97. M.S. Pino, and D.C. Chung The chromosomal instability pathway in colon cancer Gastroenterology 138 2010 2059 2072
98. P.J. Stephens, C.D. Greenman, B. Fu, and et al. Massive genomic rearrangement acquired in a single catastrophic event during cancer development Cell 144 2011 27 40
99. J. Drost, R.H. van Jaarsveld, B. Ponsioen, and et al. Sequential cancer mutations in cultured human intestinal stem cells Nature 521 2015 43 47
100. J.M. Carethers The cellular and molecular pathogenesis of colorectal cancer Gastroenterol Clin North Am 25 1996 737 754
101. M. Krausova, and V. Korinek Wnt signaling in adult intestinal stem cells and cancer Cell Signal 26 2014 570 579
102. S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, and et al. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer J Natl Cancer Inst 101 2009 1308 1324
103. F.A. Sinicrope, Q. Shi, T.C. Smyrk, and et al. Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes Gastroenterology 148 2015 88 99
104. A.I. Phipps, P.J. Limburg, J.A. Baron, and et al. Association between molecular subtypes of colorectal cancer and patient survival Gastroenterology 148 2015 77 87
105. S. Ogino, X. Liao, Y. Imamura, et al. Alliance for Clinical Trials in Oncology Predictive and prognostic analysis of PIK3CA mutation in stage III colon cancer intergroup trial J Natl Cancer Inst 105 2013 1789 1798
106. G. Manceau, L. Marisa, V. Boige, and et al. PIK3CA mutations predict recurrence in localized microsatellite stable colon cancer Cancer Med 4 2015 371 382
107. J. Jen, H. Kim, S. Piantadosi, and et al. Allelic loss of chromosome 18q and prognosis in colorectal cancer N Engl J Med 331 1994 213 221
108. J.M. Carethers, M.T. Hawn, J.K. Greenson, and et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer Gastroenterology 114 1998 1188 1195
109. C.R. Boland, J. Sato, H.D. Appelman, and et al. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression Nat Med 1 1995 902 909
110. B. Iacopetta TP53 mutation in colorectal cancer Hum Mutat 21 2003 271 276
111. T. Starzynska, M. Bromley, A. Ghosh, and et al. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma Br J Cancer 66 1992 558 562
112. J.M. Carethers Secondary prevention of colorectal cancer: is there an optimal follow-up for patients with colorectal cancer? Curr Colorectal Cancer Rep 6 2010 24 29
113. K. Ng, J.A. Meyerhardt, A.T. Chan, and et al. Aspirin and COX-2 inhibitor use in patients with stage III colon cancer J Natl Cancer Inst 107 2014 345
114. P.M. Rothwell, M. Wilson, C.E. Elwin, and et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials Lancet 376 2010 1741 1750
115. E.J. Jacobs, M.J. Thun, E.B. Bain, and et al. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence J Natl Cancer Inst 99 2007 608 615
116. J.A. Baron, B.F. Cole, R.S. Sandler, and et al. A randomized trial of aspirin to prevent colorectal adenomas N Engl J Med 348 2003 891 899
117. R.S. Sandler, S. Halabi, J.A. Baron, and et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer N Engl J Med 348 2003 883 890
118. N. Arber, J. Spicak, I. Rácz, and et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial Am J Gastroenterol 106 2011 1135 1146
119. J.A. Baron, R.S. Sandler, R.S. Bresalier, et al. APPROVe Trial Investigators A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas Gastroenterology 131 2006 1674 1682
120. J. Galon, A. Costes, F. Sanchez-Cabo, and et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome Science 313 2006 1960 1964
121. S.-Y. Lee, H. Chung, B. Devaraj, and et al. Elevated microsatellite alterations at selected tetranucleotide repeats are associated with morphologies of colorectal neoplasia Gastroenterology 139 2010 1519 1525
122. S. Tseng-Rogenski, H. Chung, M.B. Wilk, and et al. Oxidative stress induces nuclear-to-cytosol shift of MSH3, a potential mechanism for EMAST in colorectal cancer cells PLoS One 7 2012 e50616
123. S. Tseng-Rogenski, Y. Hamaya, D.Y. Choi, and et al. Interleukin 6 alters localization of hMSH3, leading to DNA mismatch repair defects in colorectal cancer cells Gastroenterology 148 2015 579 589
124. J.M. Carethers, M. Koi, and S.S. Tseng-Rogenski EMAST is a form of microsatellite instability that is initiated by inflammation and modulates colorectal cancer progression Genes 6 2015 185 205
125. A.C. Haugen, A. Goel, K. Yamada, and et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer Cancer Res 68 2008 8465 8472
126. K. Yamada, S. Kanazawa, J. Koike, and et al. Microsatellite instability at tetranucleotide repeats in sporadic colorectal cancer in Japan Oncol Rep 23 2010 551 561
127. S.-Y. Lee, K. Miyai, H.S. Han, and et al. Microsatellite instability, EMAST, and morphology associations with T cell infiltration in colorectal neoplasia Dig Dis Sci 57 2012 72 78
128. C. Campregher, G. Schmid, F. Ferk, and et al. MSH3-deficiency initiates EMAST without oncogenic transformation of human colon epithelial cells PLoS One 7 2012 e50541
129. Y. Hamaya, C. Guarinos, S.S. Tseng-Rogenski, and et al. Efficacy of 5-fluorouracil adjuvant therapy for patients with EMAST-positive stage II/III colorectal cancers PLoS One 10 2015 e0127591
130. J.M. van Oers, Y. Edwards, R. Chahwan, and et al. The MutSβ complex is a modulator of p53-driven tumorigenesis through its functions in both DNA double-strand break repair and mismatch repair Oncogene 33 2014 3939 3946
131. F. Dietlein, L. Thelen, M. Jokic, and et al. A functional cancer genomics screen identifies a druggable synthetic lethal interaction between MSH3 and PRKDC Cancer Discov 4 2014 592 605
132. M. Takahashi, M. Koi, F. Balaguer, and et al. MSH3 mediates sensitization of colorectal cancer cells to cisplatin, oxaliplatin, and a poly(ADP-ribose) polymerase inhibitor J Biol Chem 286 2011 12157 12165
133. J.M. Park, S. Huang, D. Tougeron, and et al. MSH3 mismatch repair protein regulates sensitivity to cytotoxic drugs and a histone deacetylase inhibitor in human colon carcinoma cells PLoS One 8 2013 e65369
134. J.M. Carethers DNA testing and molecular screening for colon cancer Clin Gastroenterol Hepatol 12 2014 377 381
135. J. Tol, M. Koopman, A. Cats, and et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer N Engl J Med 360 2009 563 572
136. E. Van Cutsem, C.H. Köhne, E. Hitre, and et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer N Engl J Med 360 2009 1408 1417
137. J. Kaur, and S.N. Sanyal PI3-kinase/Wnt association mediates COX-2/PGE(2) pathway to inhibit apoptosis in early stages of colon carcinogenesis: chemoprevention by diclofenac Tumour Biol 31 2010 623 631
138. X. Liao, P. Lochhead, R. Nishihara, and et al. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival N Engl J Med 367 2012 1596 1606
139. M. Yan, R.M. Rerko, P. Platzer, and et al. 15-Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers Proc Natl Acad Sci U S A 101 2004 17468 17473
140. M.G. Backlund, J.R. Mann, V.R. Holla, and et al. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer J Biol Chem 280 2005 3217 3223
141. H.R. Roberts, H.J. Smartt, A. Greenhough, and et al. Colon tumour cells increase PGE(2) by regulating COX-2 and 15-PGDH to promote survival during the microenvironmental stress of glucose deprivation Carcinogenesis 32 2011 1741 1747
142. S.P. Fink, M. Yamauchi, R. Nishihara, and et al. Aspirin and the risk of colorectal cancer in relation to the expression of 15-hydroxyprostaglandin dehydrogenase (HPGD) Sci Transl Med 6 2014 233re2
143. J.M. Carethers Proteomics, genomics and molecular biology in the personalized treatment of colorectal cancer J Gastrointest Surg 16 2012 1648 1650
144. J.M. Carethers Systemic treatment of advanced colorectal cancer - tailoring therapy to the tumor Ther Adv Gastroenterol 1 2008 33 42
145. C. Bettegowda, M. Sausen, R.J. Leary, and et al. Detection of circulating tumor DNA in early- and late-stage human malignancies Sci Transl Med 6 2014 224ra24
146. A. Calon, E. Lonardo, A. Berenguer-Llergo, and et al. Stromal gene expression defines poor-prognosis subtypes in colorectal cancer Nat Genet 47 2015 320 329
147. J.M. Carethers Screening for colorectal cancer in African Americans: Determinants and rationale for an earlier age to commence screening Dig Dis Sci 60 2015 711 721
148. A. Belcheva, T. Irrazabal, S.J. Robertson, and et al. Gut microbial metabolism drives transformation of MSH2-deficient colon epithelial cells Cell 158 2014 288 299